Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases - PubMed

Affiliations

• PMID: 10602697
• DOI: 10.1021/jm9904295

Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases

L Sun et al. J Med Chem. 1999.

Abstract

Receptor tyrosine kinases (RTKs) have been implicated as therapeutic targets for the treatment of human diseases including cancers, inflammatory diseases, cardiovascular diseases including arterial restenosis, and fibrotic diseases of the lung, liver, and kidney. Three classes of 3-substituted indolin-2-ones containing propionic acid functionality attached to the pyrrole ring at the C-3 position of the core have been identified as catalytic inhibitors of the vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) RTKs. Some of the compounds were found to inhibit the tyrosine kinase activity associated with isolated vascular endothelial growth factor receptor 2 (VEGF-R2) [fetal liver tyrosine kinase 1 (Flk-1)/kinase insert domain-containing receptor (KDR)], fibroblast growth factor receptor (FGF-R), and platelet-derived growth factor receptor (PDGF-R) tyrosine kinase with IC(50) values at nanomolar level. Thus, compound 1 showed inhibition against VEGF-R2 (Flk-1/KDR) and FGF-R1 tyrosine kinase activity with IC(50) values of 20 and 30 nM, respectively, while compound 16f inhibited the PDGF-R tyrosine kinase activity with IC(50) value of 10 nM. Structural models and structure-activity relationship analysis of these compounds for the target receptors are discussed. The cellular activities of these compounds were profiled using cellular proliferation assays as measured by bromodeoxyuridine (BrdU) incorporation. Specific and potent inhibition of cell growth was observed for some of these compounds. These data provide evidence that these compounds can be used to inhibit the function of these target receptors.

Similar articles

• Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.

  Sun L, Tran N, Liang C, Hubbard S, Tang F, Lipson K, Schreck R, Zhou Y, McMahon G, Tang C. Sun L, et al. J Med Chem. 2000 Jul 13;43(14):2655-63. doi: 10.1021/jm9906116. J Med Chem. 2000. PMID: 10893303

• A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.

  Waltenberger J, Uecker A, Kroll J, Frank H, Mayr U, Bjorge JD, Fujita D, Gazit A, Hombach V, Levitzki A, Böhmer FD. Waltenberger J, et al. Circ Res. 1999 Jul 9;85(1):12-22. doi: 10.1161/01.res.85.1.12. Circ Res. 1999. PMID: 10400906

• FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition.

  Cross MJ, Claesson-Welsh L. Cross MJ, et al. Trends Pharmacol Sci. 2001 Apr;22(4):201-7. doi: 10.1016/s0165-6147(00)01676-x. Trends Pharmacol Sci. 2001. PMID: 11282421 Review.

• Molecular approaches to receptors as targets for drug discovery.

  Evans DB, Traxler P, García-Echeverría C. Evans DB, et al. EXS. 2000;89:123-39. doi: 10.1007/978-3-0348-8393-1_8. EXS. 2000. PMID: 10997286 Review.

Cited by

• Kinase inhibitors as potential agents in the treatment of multiple myeloma.

  Abramson HN. Abramson HN. Oncotarget. 2016 Dec 6;7(49):81926-81968. doi: 10.18632/oncotarget.10745. Oncotarget. 2016. PMID: 27655636 Free PMC article. Review.

• Benchmarking sets for molecular docking.

  Huang N, Shoichet BK, Irwin JJ. Huang N, et al. J Med Chem. 2006 Nov 16;49(23):6789-801. doi: 10.1021/jm0608356. J Med Chem. 2006. PMID: 17154509 Free PMC article.

• Muscle precursor cell movements in zebrafish are dynamic and require Six family genes.

  Talbot JC, Teets EM, Ratnayake D, Duy PQ, Currie PD, Amacher SL. Talbot JC, et al. Development. 2019 May 15;146(10):dev171421. doi: 10.1242/dev.171421. Development. 2019. PMID: 31023879 Free PMC article.

• PDGF Modulates BMP2-Induced Osteogenesis in Periosteal Progenitor Cells.

  Wang X, Matthews BG, Yu J, Novak S, Grcevic D, Sanjay A, Kalajzic I. Wang X, et al. JBMR Plus. 2019 Jan 15;3(5):e10127. doi: 10.1002/jbm4.10127. eCollection 2019 May. JBMR Plus. 2019. PMID: 31131345 Free PMC article.

• Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships.

  Asquith CRM, East MP, Laitinen T, Alamillo-Ferrer C, Hartikainen E, Wells CI, Axtman AD, Drewry DH, Tizzard GJ, Poso A, Willson TM, Johnson GL. Asquith CRM, et al. Eur J Med Chem. 2024 May 5;271:116357. doi: 10.1016/j.ejmech.2024.116357. Epub 2024 Apr 2. Eur J Med Chem. 2024. PMID: 38636130 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Chemical Society

• Other Literature Sources

  • The Lens - Patent Citations Database

• Chemical Information

  • BindingDB

• Molecular Biology Databases

  • Guide to Pharmacology

• Miscellaneous

  • NCI CPTAC Assay Portal